| Literature DB >> 31744157 |
Balsam R Rizeq1,2, Nadin N Younes3, Kashif Rasool4, Gheyath K Nasrallah2,3.
Abstract
The development of advanced nanomaterials and technologies is essential in biomedical engineering to improve the quality of life. Chitosan-based nanomaterials are on the forefront and attract wide interest due to their versatile physicochemical characteristics such as biodegradability, biocompatibility, and non-toxicity, which play a promising role in biological applications. Chitosan and its derivatives are employed in several applications including pharmaceuticals and biomedical engineering. This article presents a comprehensive overview of recent advances in chitosan derivatives and nanoparticle synthesis, as well as emerging applications in medicine, tissue engineering, drug delivery, gene therapy, and cancer therapy. In addition to the applications, we critically review the main concerns and mitigation strategies related to chitosan bactericidal properties, toxicity/safety using tissue cultures and animal models, and also their potential environmental impact. At the end of this review, we also provide some of future directions and conclusions that are important for expanding the field of biomedical applications of the chitosan nanoparticles.Entities:
Keywords: Chitosan; biomedical; nanoparticles; pharmaceuticals; toxicity
Year: 2019 PMID: 31744157 PMCID: PMC6888098 DOI: 10.3390/ijms20225776
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Schematic illustration of different methods of chitosan nanoparticle (ChNP) synthesis.
Figure 2Schematic of facile preparation of bio-nanocomposite based on chitosan (Ch) and graphene oxide (GO) and silver (Ag) nanohybrids for controlled release of an anticancer drug [43].
Field of application potentials of chitosan (Ch) and its derivatives [105].
| Applications | Functions | References |
|---|---|---|
| Antimicrobial agent | Bactericidal and fungistatic | [ |
| Food industry | Preservative, food stabilizer, gelling agent, food additive, controlled enzymatic browning in fruits, controlled release of antioxidants, controlled moisture, temperature control, color stabilization, etc. | [ |
| Biotechnology | Protein separation, chromatographic media, enzyme immobilization, catalyst, imaging, dialysis, filtration, etc. | [ |
| Agriculture | Fertilizer, seed coating, etc. | [ |
| Medical applications | Clotting agent, wound healing and tissue engineering, skin burn, surgical sutures, blood cholesterol control, antitumor agent, membranes and scaffolds, etc. | [ |
| Cosmetics | Skin and hair products | [ |
| Delivery | Controlled drug delivery, gene delivery, oral peptide and protein delivery, small interfering RNA (siRNA) delivery, etc. | [ |
Figure 3Representative photographs of the macroscopic appearance of wounds healing for groups treated with physiological serum (control), CICAFLORA®, chitosan (CS), CS–polyvinyl alcohol (PVA), and CS–silver nanoparticle (AgNP) gels [124].
A summary of Ch and its derivatives with their most important anticancer activities [78].
| Chitosan and Its Derivatives | In Vitro Cell Lines and In Vivo Models | Function | References |
|---|---|---|---|
| Carboxymethyl chitosan | BEL-7402 cell line | - Inhibited lung metastasis in mouse model | [ |
| Carboxymethyl chitosan | Apoptosis models in | - Carboxymethyl chitosan, increased Bcl-2 activity and decreased Bax, caspase-3, and caspase-9 activities | [ |
| Chitosan | RPMI7951, SKMEL28, and A375 | Chitosan was coated in culture wells of RPMI7951, SKMEL28, and A375. | [ |
| Chitosan | Transplantation of meth-A solid tumor in BALBc mice | Interleukin 1 and 2 induction and proliferation of cytolytic T lymphocytes, enhancing the anticancer activity | [ |
| Chitosan | LCC and HepG2 cell line xenografts in mouse model | - S-phase arrest and inhibition of DNA synthesis | [ |
| Chitosan | HepG2, A549, and PC3 cell line | Suppression of HepG2, A549, and PC3 cancer cell growth via 50% cell death | [ |
MMP-9: Matrix metallopeptidase 9; Bcl-2: B-cell lymphoma 2; Bax: Bcl-2-associated X protein; CD95: Cell adhesion 95 also known as Fas; FasL: Fas ligand; S-phase: DNA synthesis phase in cell cycle; CDK-2: Cyclin-dependent kinase 2.
Figure 4Summary figure representing the toxicity of different sizes of ChNPs, Tween modified Ch and Ch zinc oxide nanoparticles on zebrafish embryo. 4 studies investigated the toxicity of different sizes of ChNPs (100–340 nm). The smallest ChNPs tested for its toxicity sized 84.86 nm, in which it showed dose-dependent increase in mortality rate (LC50 280 mg/L), decrease in the hatching rate. 200 mg/L of ChNPs size ranging from 100 to 150 nm showed minor neurotoxicity (hyperactivity) and liver necrosis. 30 mg/L of ChNPs size 200 nm showed a significant decrease in the hatching rate. 12 mg/L of ChNPs size 247 nm showed significantly decreased hatching rate, increased mortality and neurobehavioral toxicity (hyperactivity). 20 mg/L of ChNPs size 340 nm showed significantly decreased hatching rate. The Tween modified ChNPs (TmCS-NPs) size 251 nm showed significantly decreased hatching rate as well. However, it showed a decrease in neural activity (Neurobehavioral toxicity) at very low concentration as 12 mg/L. Finally, Ch/zinc-oxide nanoparticles (CZNC) size 120 to 150 nm showed only minor hepatotoxicity (liver necrosis) at only high concentrating (250 mg/L).
Summary of the five studies of chitosan nanoparticle toxicity using a zebrafish model.
| Nanoparticle | LC50 (mg/L) | Particle Size | Teratogenicity | Assays | Reference |
|---|---|---|---|---|---|
| ChNPs | 23.26 mg/L | 247 ± 20 nm | Uninflated swim bladder and bent spine | Mortality rate, hatching rate, malformations, neurobehavioral activity assessments and apoptosis assay | [ |
| Tween modified ChNPs (TmCS-NPs) | 25.06 mg/L | 251 ± 15 nm | Uninflated swim bladder and bent spine | [ | |
| ChNPs | Not recorded | 200 nm | Dose-dependent decrease in hatching rate; malformations including a bent spine, pericardial edema, and an opaque yolk in zebrafish embryos; increase in heat-shock protein | Acridine orange staining and Western blot | [ |
| ChNPs | Not-Recorded | 340 nm | Dose-dependent decrease in hatching rate | Acridine orange staining and Western blot | [ |
| ChNPs | >200 mg/L | 100–150 nm | no mortality, but morphological abnormalities; neurotoxic effects and significant impairment of liver size | Organ-specific toxicity (cardiac, hepatic, and neuromuscular) | [ |
| ChNPs | 280 mg/L | 84.86 nm | Decrease in the hatching rate and dose-dependent mortality rate | Mortality rate and hatching rate | [ |
| Ch/zinc-oxide nanoparticles (CZNC) | >250 mg/L | 120–150 nm | No cardiotoxic or neurotoxic effects and minor hepatotoxic effect | Organ-specific toxicity (cardiac, hepatic, and neuromuscular) | [ |